Frequency of follow-up care for adult and pediatric patients during initiation of antidepressant therapy

American Journal of Managed Care

Volumn 12, Issue 8, 2006, Pages 453-461

  Stettin, Glen D ^a   Yao, Jianying ^a   Verbrugge, Robert R ^a   Aubert, Ronald E ^a  

^a Medco Health Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AMBULATORY CARE; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG LABELING; DRUG SAFETY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MENTAL HEALTH CARE; NEWBORN; PACKAGING; PATIENT CARE; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTINUITY OF PATIENT CARE; DEPRESSION; FEMALE; HUMANS; MALE; NEW ENGLAND; OFFICE VISITS; PEDIATRICS; RETROSPECTIVE STUDIES;

EID: 33747627646     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Food and Drug Administration. Labeling change request letter for antidepressant medications. October 15, 2004. Available at: http://www.fda.gov/ cder/drug/antidepressants/SSRIIabelChange.htm. Accessed May 15, 2006.
2. Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications [FDA public health advisory]. October 15, 2004. Available at: http://www.fda.gov/cder/drug/antidepressants/ SSRIPHA200410.htm. Accessed May 15, 2006.
3. Food and Drug Administration. Class suicidality labeling language for antidepressants. Available at: http://www.fda.gov/cder/drug/antidepressants/ PI_template. pdf. Accessed May 15, 2006.
4. Food and Drug Administration. Medication guide about using antidepressants in children and teenagers. Available at: http://www.fda.gov/ cder/drug/antidepressants/MG_template.pdf. Accessed May 15, 2006.
5. Mosholder AD. Suicidality in pediatric clinical trials of antidepressant drugs: comparison between previous analyses and Columbia University classification [FDA memorandum]. August 16, 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-11-TAB09a-Mosholder- review.pdf. Accessed May 15, 2006.
6. Hammad TA. Relationship between psychotropic drugs and pediatric suicidality [FDA review]. August 16, 2004. Available at: http://www.fda.gov/ ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. Accessed May 15, 2006.
7. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-343.
8. Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant medications [FDA public health advisory]. March 22, 2004. Available at: http://www.fda.gov/cder/drug/ antidepressants/AntidepressanstPHA. htm. Accessed May 15, 2006.
9. Food and Drug Administration. Suicidality in adults being treated with antidepressant medications [FDA public health advisory]. June 30, 2005. Available at: http://www.fda.gov/cder/drug/advisory/SSRI200507.htm. Accessed May 15, 2006.
10. Work Group on Major Depressive Disorder, American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(4 suppl):1-45.
11. Depression Guideline Panel, Agency for Health Care Policy and Research. Treatment of Major Depression. Rockville, Md: US Department of Health and Human Services: 1993. AHCPR publication 93-0551. Depression in Primary Care; vol 2.
12. Snow V, Lascher S, Mottur-Pilson C, for the American College of Physicians-American Society of Internal Medicine. Pharmacologic treatment of acute major depression and dysthymia. Ann Intern Med. 2000;132:738-742.
13. Brigham and Women's Hospital. Depression: A Guide to Diagnosis and Treatment. Boston, Mass: Brigham and Women's Hospital; 2001.
14. Institute for Clinical Systems Improvement. Major Depression in Adults for Mental Health Care. Bloomington, Minn: Institute for Clinical Systems Improvement; 2003.
15. University of Michigan Health System. Depression. Ann Arbor, Mich: University of Michigan Health System; 2004.
16. Care Management Institute, Kaiser Permanente. Adult Primary Care Depression Guidelines. Oakland, Calif: Kaiser Permanente; 2004.
17. Work Group on Panic Disorder, American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry. 1998;155(4 suppl):1-34.
18. Campbell-Sills L, Stein MB. Guideline Watch: Practice Guideline for the Treatment of Patients With Panic Disorder. Arlington, Va: American Psychiatric Association; 2006. Available at: http://www.psych.org/psych_pract/treatg/pg/ prac_guide.cfm. Accessed May 15, 2006.
19. American Psychiatric Association, Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder. Arlington, Va: American Psychiatric Association; 2004. Available at: http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm. Accessed May 15, 2006.
20. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
21. National Committee for Quality Assurance. Antidepressant medication management: the state of health care quality 2004. Available at: http://www.ncqa. org/communications/sohc2004/antidepressant_medication.htm. Accessed May 15, 2006.
22. Schulberg HC, Katon W, Simon GE, Rush J. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research practice guidelines. Arch Gen Psychiatry. 1998;55:1121-1127.
23. Simon GE, Von Korff M, Rutter CM, Peterson DA. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry. 2001;58:395-401.
24. Richardson LP, DiGiuseppe D, Christakis DA, McCauley E, Katon W. Quality of care for Medicaid-covered youth treated with antidepressant therapy. Arch Gen Psychiatry. 2004;61:475-480.
25. National Committee for Quality Assurance. HEDIS® 2004 Technical Specifications. Washington, DC: National Committee for Quality Assurance; 2003.
26. Food and Drug Administration. Transcripts, Joint Meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. September 13-14, 2004. Available at: http://www.fda.gov/ohrms/ dockets/ac/cder04.html#PsychopharmacologicDrugs. Accessed May 15, 2006.
27. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005;330(7488):385.
28. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396.
29. Wessely S, Kerwin R. Suicide risk and the SSRIs. JAMA. 2004;292:379-381.
30. Jones MT, Cockrum PC. A critical review of published economic modelling studies in depression. Pharmacoeconomics. 2000;17:555-583.
31. Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice: eight-month clinical outcomes. Arch Gen Psychiatry. 1996;53:913-919.
32. Schulberg HC, Block MR, Madonia MJ, et al. The "usual care" of major depression in primary care practice. Arch Fam Med. 1997;6:334-339.
33. Gilbody S, Whitty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA. 2003;289:3145-3151.
34. Simon GE, Ludman EJ, Tutty S, Operskalski B, Von Korff M. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA. 2004;292:935-942.
35. Dietrich AJ, Oxman TE, Williams JW Jr, et al. Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. BMJ. 2004;329(7466):602.
36. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry. 1998;55:645-651.
37. American Medical Association. AMA asks FDA to study impact of antidepressant labeling changes. Available at: http://www.ama-assn.org/ama/pub/ category/15240.html. Accessed May 15, 2006.
38. National Institute of Mental Health. Depression. Bethesda, Md: National Institute of Mental Health; 2000. NIH publication 00-3561.
39. National Disease and Therapeutic Index [database online]. Plymouth Meeting, Pa: IMS Health; 2005. Updated September 8, 2005.
40. National Committee for Quality Assurance. The State of Health Care Quality: 2004. Washington, DC: National Committee for Quality Assurance; 2004.